Abstract:Familial partial lipodystrophy 3 (FPLD3) is a rare genetic disorder caused by loss-of-function mutations in the PPARG gene, characterized by a selective absence of subcutaneous fat and associated metabolic complications. However, the molecular mechanisms of FPLD3 remain unclear. In this study, we recruited a 17-yr-old Chinese female with FPLD3 and her family, identifying a novel PPARG frameshift mutation (exon 4: c.418dup: p.R140Kfs*7) that truncates the PPARγ protein at the seventh amino acid, significantly expanding the genetic landscape of FPLD3. By performing next-generation sequencing of circular RNAs (circRNAs), microRNAs (miRNAs), and mRNAs in plasma exosomes, we discovered 59 circRNAs, 57 miRNAs, and 299 mRNAs were significantly altered in the mutation carriers compared with the healthy controls. Integration analysis highlighted that the circ_0001597-miR-671-5p pair and 18 mRNAs might be incorporated into the metabolic regulatory networks of the FPLD3 induced by the novel PPARG mutation. Functional annotation suggested that these genes were significantly enriched in glucose- and lipid metabolism-related pathways. Among the circRNA-miRNA-mRNA network, we identified two critical regulators, early growth response-1 (EGR1), a key transcription factor known for its role in insulin signaling pathways and lipid metabolism, and 1-acylglycerol-3-phosphate O-acyltransferase 3 (AGPAT3), which gets involved in the biosynthesis of triglycerides and lipolysis. Circ_0001597 regulates the expression of these genes through miR-671-5p, potentially contributing to the pathophysiology of FPLD3. Overall, this study clarified a circulating exosomal circRNA-miRNA-mRNA network in a FPLD3 family with a novel PPARG mutation, providing evidence for exploring promising biomarkers and developing novel therapeutic strategies for this rare genetic disorder.NEW & NOTEWORTHY Through the establishment of a ceRNA regulatory networks in a novel PPARG frameshift mutation c.418dup-induced FPLD3 pedigree, this study reveals that circ_0001597 may contribute to the pathophysiology of FPLD3 by sequestering miR-671-5p to regulate the expression of EGR1 and AGPAT3, pivotal genes situated in the triglyceride (TG) synthesis and lipolysis pathways. Current findings expand our molecular understanding of adipose tissue dysfunction, providing potential blood biomarkers and therapeutic avenues for lipodystrophy and associated metabolic complications.

Lipodystrophy Prevalence, "Lipodystrophy-Like Phenotypes," and Diagnostic Challenges

Relationship of fat mass ratio - a biomarker for lipodystrophy - with cardiometabolic traits

Phenotypic Differences Among Familial Partial Lipodystrophy Due to LMNA or PPARG Variants

Familial partial lipodystrophy syndromes

Anthropometric measurements as a key diagnostic tool for familial partial lipodystrophy in women

Comprehensive analysis of morbidity and mortality patterns in familial partial lipodystrophy patients: insights from a population study

Diagnostic strategies and clinical management of lipodystrophy.

A cohort analysis of familial partial lipodystrophy from two Mediterranean countries

Phenotypic and molecular reanalysis of a cohort of patients with monogenic diabetes reveals a case of partial lipodystrophy due to the A8344G mutation in the mitochondrial DNA

Precision medicine: toward restoring fat with gene therapy in inherited lipodystrophy

Pancreatic fat deposition is increased and related to beta-cell function in women with familial partial lipodystrophy

Familial partial lipodystrophy resulting from loss-of-function PPARγ pathogenic variants: phenotypic, clinical, and genetic features

Whole-exome Sequencing Identifies ADRA2A Mutation in Atypical Familial Partial Lipodystrophy

Modern prevalence of the Fredrickson-Levy-Lees dyslipidemias: findings from the Very Large Database of Lipids and National Health and Nutrition Examination Survey

Familial Partial Lipodystrophy With Gene Mutation In Both Lmna And Pparg: Report Of A Case And Review Of Literature

Clinical and imaging features of women with polygenic partial lipodystrophy: a case series

Acquired partial lipodystrophy is associated with increased risk for developing metabolic abnormalities

A rapid action plan to improve diagnosis and management of lipodystrophy syndromes

Diagnosis, treatment and management of lipodystrophy: the physician perspective on the patient journey

Multiple symmetric and multiple familial lipomatosis

Circulating exosomal circRNA-miRNA-mRNA network in a familial partial lipodystrophy type 3 family with a novel PPARG frameshift mutation c.418dup